PHARMAC is pleased to announce that the approval of an agreement with Valeant Pharmaceuticals (NZ) Limited. In summary, the effect of the decision is that:

• There will be a reduction in price and subsidy of the following flecainide acetate products: 50 mg tablets (Tambocor), 100 mg long-acting capsules (Tambocor CR) and 200 mg long-acting capsules (Tambocor CR) from 1 August 2014
• Flecainide acetate 100 mg tablets will be delisted from the Pharmaceutical Schedule once current New Zealand stock is exhausted
• The Tambocor brand of flecainide injection, 10 mg per ml, 15 ml ampoule will remain listed at the current price and subsidy
• There will be subsidy and delisting protection for the Tambocor brand of flecainide acetate until 31 July 2017
• The Qvar brand of extra fine beclometasone dipropionate aerosol inhalers will be listed on the Pharmaceutical Schedule from 1 September 2014

For more details, go to: http://www.pharmac.health.nz/news/notification-2014-07-11-flecainide-and-beclometasone/